GL Chemtech appoints Dr. John Warner as Green Chemistry Innovation Advisor

Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster

The European Commission will review the CHMP recommendation and is expected to make a final decision soon.

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Thermo Fisher Scientific emphasizes on the need for more disruptive technologies

Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.

Pfizer and BioNTech submit application to USFDA for emergency use authorization of Omicron BA.4/BA.5-adapted bivalent vaccine booster for 5-11 year age

The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Olympus Corp aims to strengthen MedTech industry with startups, says GlobalData

Olympus Corp was the market leader for endoscopy devices, accounting for around 23% of the global market in 2021.

World’s first intra nasal vaccine iNCOVACC from Bharat Biotech receives approval

iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.1-adapted bivalent COVID-19 vaccine booster in EU

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine